178 related articles for article (PubMed ID: 6198342)
1. Comparison of a new tumour marker, CA 19-9, with alpha-fetoprotein and carcinoembryonic antigen in patients with upper gastrointestinal diseases.
Jalanko H; Kuusela P; Roberts P; Sipponen P; Haglund CA; Mäkelä O
J Clin Pathol; 1984 Feb; 37(2):218-22. PubMed ID: 6198342
[TBL] [Abstract][Full Text] [Related]
2. Comparison of CA-50, a new tumour marker, with carcinoembryonic antigen (CEA) and alpha-fetoprotein (AFP) in patients with gastrointestinal diseases.
Kuusela P; Haglund C; Roberts PJ; Jalanko H
Br J Cancer; 1987 Jun; 55(6):673-6. PubMed ID: 2441731
[TBL] [Abstract][Full Text] [Related]
3. Comparison of a new tumour marker CA 242 with CA 19-9, CA 50 and carcinoembryonic antigen (CEA) in digestive tract diseases.
Kuusela P; Haglund C; Roberts PJ
Br J Cancer; 1991 Apr; 63(4):636-40. PubMed ID: 2021550
[TBL] [Abstract][Full Text] [Related]
4. Tumour marker antigen CA125 in pancreatic cancer: a comparison with CA19-9 and CEA.
Haglund C
Br J Cancer; 1986 Dec; 54(6):897-901. PubMed ID: 3467786
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of CA 19-9 as a serum tumour marker in pancreatic cancer.
Haglund C; Roberts PJ; Kuusela P; Scheinin TM; Mäkelä O; Jalanko H
Br J Cancer; 1986 Feb; 53(2):197-202. PubMed ID: 3456787
[TBL] [Abstract][Full Text] [Related]
6. Tumour markers in pancreatic cancer.
Haglund C; Roberts PJ; Kuusela P; Jalanko H
Scand J Gastroenterol Suppl; 1986; 126():75-8. PubMed ID: 3470921
[TBL] [Abstract][Full Text] [Related]
7. Comparative studies of DU-PAN-2, carcinoembryonic antigen, and CA19-9 in the serum and bile of patients with pancreatic and biliary tract diseases: evaluation of the influence of obstructive jaundice.
Ohshio G; Manabe T; Watanabe Y; Endo K; Kudo H; Suzuki T; Tobe T
Am J Gastroenterol; 1990 Oct; 85(10):1370-6. PubMed ID: 2220731
[TBL] [Abstract][Full Text] [Related]
8. A clinical evaluation of carbohydrate antigen 19-9 and carcinoembryonic antigen in patients with pancreatic carcinoma.
Satake K; Kanazawa G; Kho I; Chung YS; Umeyama K
J Surg Oncol; 1985 May; 29(1):15-21. PubMed ID: 3857396
[TBL] [Abstract][Full Text] [Related]
9. Carbohydrate antigenic determinant (CA 19-9) and other tumor markers in gastrointestinal malignancies.
Yoshikawa T; Nishida K; Tanigawa M; Fukumoto K; Kondo M
Digestion; 1985; 31(2-3):67-76. PubMed ID: 2581838
[TBL] [Abstract][Full Text] [Related]
10. Serum and pancreatic juice carcinoembryonic antigen in pancreatic and biliary disease.
Carr-Locke DL
Gut; 1980 Aug; 21(8):656-61. PubMed ID: 7429329
[TBL] [Abstract][Full Text] [Related]
11. Tumor markers carbohydrate antigens CA 19-9 and CA-50 and carcinoembryonic antigen in pancreatic cancer and benign diseases of the pancreatobiliary tract.
Harmenberg U; Wahren B; Wiechel KL
Cancer Res; 1988 Apr; 48(7):1985-8. PubMed ID: 3349472
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of serum CA125 values in patients with cancers of the digestive system.
Haga Y; Sakamoto K; Egami H; Yoshimura R; Mori K; Akagi M
Am J Med Sci; 1986 Jul; 292(1):30-4. PubMed ID: 3459357
[TBL] [Abstract][Full Text] [Related]
13. [Comparison between the gastrointestinal tumor antigen and the carcinoembryonic antigen in diseases of the digestive tract].
Tappero G; Piantino P; Cerchier A; Pecchio F
Minerva Med; 1985 Apr; 76(16):765-70. PubMed ID: 2582313
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of serum pancreatic enzymes, carbohydrate antigen 19-9, and carcinoembryonic antigen in various pancreatic diseases.
Satake K; Kanazawa G; Kho I; Chung Y; Umeyama K
Am J Gastroenterol; 1985 Aug; 80(8):630-6. PubMed ID: 2411125
[TBL] [Abstract][Full Text] [Related]
15. Serum levels of CA 125 in patients with gastrointestinal cancers.
Omar YT; al-Naqeeb N; el Nas SA; Awwad AH; Foudeh MO; Safadi NB; Nasralla MY; Ali MA; Szymendera JJ
Tumour Biol; 1989; 10(6):316-23. PubMed ID: 2480631
[TBL] [Abstract][Full Text] [Related]
16. Tumour marker CA 125 in patients with digestive tract malignancies.
Haglund C; Kuusela P; Roberts P; Jalanko H
Scand J Clin Lab Invest; 1991 May; 51(3):265-270. PubMed ID: 1715601
[TBL] [Abstract][Full Text] [Related]
17. Comparison of CA 72-4 with CA 19-9 and carcinoembryonic antigen in the serodiagnostics of gastrointestinal malignancies.
Heptner G; Domschke S; Domschke W
Scand J Gastroenterol; 1989 Aug; 24(6):745-50. PubMed ID: 2814339
[TBL] [Abstract][Full Text] [Related]
18. Estimation of carbohydrate antigen (CA) 19-9 levels in pure pancreatic juice of patients with pancreatic cancer.
Nishida K; Tasaki N; Miyagawa H; Yoshikawa T; Kondo M
Am J Gastroenterol; 1988 Feb; 83(2):126-9. PubMed ID: 3422536
[TBL] [Abstract][Full Text] [Related]
19. Detection of an oncofetal antigen (DU-PAN-2) in sera of patients with non-malignant hepatobiliary diseases and hepatomas.
Haviland AE; Borowitz MJ; Killenberg PG; Lan MS; Metzgar RS
Int J Cancer; 1988 Jun; 41(6):789-93. PubMed ID: 2836318
[TBL] [Abstract][Full Text] [Related]
20. Prospective evaluation of the diagnostic efficacy of CA 19-9 assay as a marker for gastrointestinal cancers.
Andriulli A; Gindro T; Piantino P; Farini R; Cavallini G; Piazzi L; Naccarato R; Dobrilla G; Verme G; Scuro LA
Digestion; 1986; 33(1):26-33. PubMed ID: 3940235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
